We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ziopharm Oncology has announced findings from a Phase I study of ZIO-101, a proprietary organic arsenic, showing that 43 percent of relapsing, progressing multiple myeloma patients experienced stable disease and that the drug was well tolerated in all 14 patients in the study group.
Neurobiological Technologies has presented new analysis of data from ongoing clinical trials of Viprinex, and the company has announced it plans to initiate two new Phase III trials of the drug.
Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) have begun patient dosing in BLISS-76, one of two pivotal Phase III clinical trials of LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus (SLE).
Ista Pharmaceuticals has announced highly statistically significant results from its initial analysis of the Phase III clinical trials of its Xibrom once-daily formulation.
Alpharma has results of a Phase IV study of Kadian (morphine sulfate extended-release) that demonstrate the pharmacokinetics of the long-acting opioid are not significantly affected by the consumption of alcohol.
A 1,700-patient study comparing anticoagulation therapies found that Lovenox (enoxaparin sodium), one of a class of compounds called low-molecular-weight heparins, is significantly more effective than an older therapy at preventing a dangerous and common ischemic stroke complication called venous thromboembolism (VTE), the University of Texas Health Science Center has announced.
IntelGenx Technologies and Cary Pharmaceuticals have begun enrolling subjects in the first Phase I pilot study for Cary's extended-release QuitPak formulation.
Medivir, on behalf of the Tibotec and Medivir collaborative project, announced that Tibotec has initiated a clinical trial with a potent and selective hepatitis C virus (HCV) NS3/4A protease inhibitor for the treatment of chronic HCV infection.